Novel Antitumor Agent “Yondelis® IV Infusion” Approved in Japan for Treatment of Soft Tissue Sarcoma

Taiho Pharmaceutical Co., Ltd. announced on September 28 that it received marketing approval from the Ministry of Health, Labour and Welfare for the novel antitumor agent Yondelis (nonproprietary name: trabectedin) 0.25 mg and 1 mg IV Infusion, for the treatment of patients with soft tissue sarcoma in Japan.

Yondelis is an antitumor agent developed by the Spanish company PharmaMar, S.A. It was originally isolated from the Caribbean ascidian Ecteinascidia turbinata and is now produced through semi-synthesis. Taiho Pharmaceutical entered into a license agreement with PharmaMar in 2009 to develop and commercialize the drug in Japan, and has since been engaged in its development.